Health
FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.
OriginalSourceArs TechnicaUnited StatesLeanCenter-leftCredibilityPublished14:43 UTCRatings: AllSides, MBFCSourceArs TechnicaUnited StatesLeanCenter-leftCredibilityPublished14:43 UTCRatings: AllSides, MBFC
“GLP-1 drugs may increase risk of vision loss from rare condition, FDA warns”
FDA warns GLP-1 drugs may carry rare NAION risk
Key points
- FDA warns GLP-1 drugs like Ozempic and Wegovy may carry a rare NAION risk.
- NAION is a rare eye condition caused by restricted blood flow to the optic nerve.
- FDA reviews meta-analysis and studies, finding 15 probable NAION cases in trials.
- Labeling will include a warning; providers may consider stopping GLP-1 therapy if NAION develops.
- EMA and American ophthalmology groups similarly urge caution and shared decision-making.
Other reports
- SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS NewsSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News
“FDA warns of rare vision-loss side effect from GLP-1 drugs”
- SourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at MintSourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at Mint
- SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The IndependentSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
- SourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The NationalSourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The National
“FDA orders new warning on GLP-1 drugs over potential risk of blindness”
- SourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global NewsSourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global News
- SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBCSourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC
“Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness”
- SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The GuardianSourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian
“FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications”
- SourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLineSourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLine
“FDA flags possible risk of rare eye condition with GLP-1 drugs, orders new safety warning”
How it got here
Ars Technica publishes the article.
concise.news reads it.
Grouped with 8 other reports as story 8.
The Brief ranks it 8th.
8 8 FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.